Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy

23 Jul 2012

Abstract excerpt

Lipohypertrophy in HIV-infected patients is associated with metabolic abnormalities. Raltegravir (RAL) is not known to induce fat changes or severe metabolic perturbations. HIV-infected women with central adiposity and HIV-1 RNA less than 50 copies per milliliter on non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based antiretroviral therapy (ART) continued their nucleoside...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22823027
DOI: 10.1089/apc.2012.0135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with LipohypertrophyPMID 22823027Read ↗

The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.Semantic proximity Read ↗

An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocolSemantic proximity Read ↗

Viral mechanisms of adipose dysfunction: lessons from HIV-1 VprSemantic proximity Read ↗

Effect of genetic variations in drug transporters, metabolizing enzyme and regulatory genes on the development of HIV-associated lipodystrophy.Semantic proximity Read ↗

Interventions for body habitus changes associated with HIV infection and its treatment.Semantic proximity Read ↗

A Distinct Form of Subcutaneous Fat Fibrosis Predicts Insulin Resistance in People with HIVSemantic proximity Read ↗

The 1G/1G+1G/2G Genotypes of MMP1 rs1799750 Are Associated with Higher Levels of MMP-1 and Are Both Associated with Lipodystrophy in People Living with HIV on Antiretroviral Therapy.Semantic proximity Read ↗

Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin.Semantic proximity Read ↗

Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.Semantic proximity Read ↗

Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.Semantic proximity Read ↗

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapySemantic proximity Read ↗

HIV associated lipodystrophy : study of molecular mechanisms and genetic susceptibilitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.